Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.20
(
0.68%
)
Bitcoin
77,025.31
(
-0.49%
)
News Focus
News Focus
Post# of 20689
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: olsen post# 9520

Friday, 08/03/2012 1:43:36 PM

Friday, August 03, 2012 1:43:36 PM

Post# of 20689
If manufacturing patents pertaining to FDA-approved drugs are not going to be protected, MNTA will have to rely more on trade secrets.

In no way is today's ruling a possible "death blow" for the company, IMO. Several other companies working on FoB's are in the same boat.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote